The Heartburn Drug Japan Had for Eight Years Before America Did

Not every gap between Japanese and American medicine involves a rare cancer or an experimental procedure. Sometimes it involves something as ordinary as heartburn — and the gap is still nearly a decade wide.

The drug is vonoprazan, sold in Japan since 2015 under the brand name Takecab. It represents a genuinely new class of acid-suppressing medication, developed by the Japanese pharmaceutical company Takeda. American patients could not get it at all until the FDA approved it — under the brand name Voquezna — in November 2023. That is roughly an eight-year head start for Japanese patients on a drug now considered by many gastroenterologists to be a meaningful step forward in treating acid-related disease.

How it works

For decades, the standard treatment for acid reflux, ulcers, and related conditions has been the proton pump inhibitor, or PPI — drugs like omeprazole and lansoprazole that most Americans know by brand names such as Prilosec and Prevacid. PPIs are prodrugs: they need to be activated inside the acidic environment of the stomach, which is why they are typically taken 30 minutes before a meal and can take several days to reach full effect.

Vonoprazan works differently. It belongs to a class called potassium-competitive acid blockers, or P-CABs. Rather than requiring activation, it directly and competitively blocks the potassium-binding site of the stomach’s acid pump (the H+/K+-ATPase enzyme). It binds quickly, does not require food-timed dosing, and — because its binding is slow to reverse — produces more sustained acid suppression than conventional PPIs, including stronger control overnight, when reflux symptoms are often at their worst. In Japan, it has been used to treat erosive esophagitis, gastric and duodenal ulcers, GERD, and — notably — as part of combination therapy to eradicate Helicobacter pylori, the bacterium closely linked to gastric cancer.

Where each country stands

Japan’s regulators approved vonoprazan in 2015, and it has been in routine use there for over a decade. The FDA, by contrast, approved Voquezna in stages: first for H. pylori eradication combination therapy in 2022, then for erosive esophagitis in November 2023, and finally for non-erosive GERD in July 2024 — each indication arriving years after its Japanese counterpart.

The gap was not primarily scientific; it was structural. Takeda developed and sold the drug in Japan directly, but did not bring it through U.S. trials and FDA review itself. In 2019, Takeda spun the U.S., European, and Canadian rights out to a newly formed company, Phathom Pharmaceuticals, which then had to run its own American clinical trial program and regulatory process from scratch — a process that took several more years before the first U.S. approval arrived.

Why this gap exists

This isn’t a case of American medicine lagging in ability. The FDA’s review, once Phathom’s data was in hand, proceeded through the normal, thorough approval process. The lag instead reflects something more mundane: a drug invented and proven in one country doesn’t automatically get filed, tested, and licensed in another on the same timeline. Commercial decisions, licensing deals, and separate trial requirements can add years — even for a medicine already safely used by millions of patients elsewhere.

Connecting to prevention

Vonoprazan’s role in eradicating H. pylori is where this story connects most directly to prevention. Persistent H. pylori infection is one of the strongest known risk factors for gastric cancer, and Japan — which has one of the world’s highest gastric cancer rates — has built eradication into its broader national prevention strategy alongside routine endoscopic screening. Pairing an effective eradication drug with comprehensive early detection, the kind embodied in Japan’s Ningen Dock health screenings, reflects the same underlying philosophy: catch and address risk before it becomes disease, rather than waiting to treat it after the fact.

It’s a useful reminder that the gaps between two advanced healthcare systems aren’t always about dramatic new technology. Sometimes they show up in the medicine cabinet.

---

Sources: Vonoprazan: First Global Approval, PubMed; Voquezna (vonoprazan) FDA Approval History, Drugs.com; Phathom Pharmaceuticals FDA Approval Announcement, November 2023; Phathom Pharmaceuticals FDA Approval for Non-Erosive GERD, July 2024; Takeda/Phathom Licensing History, pharmaphorum.